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Abstract 
It is demonstrated that ultraviolet B (UVB) radiation stimulates increased expression of the proopiomelanocortin (POMC) gene which 
is accompanied by production and release of et-melanocyte stimulating hormone (a-MSH) and adrenocorticotropin (ACTH) by both 
normal and malignant human melanocytes and keratinocytes. The production and release of both peptides are also stimulated by dibutyryl 
cyclic adenosine monophosphate (dbcAMP) and interleukin ha (IL-let) but not by endothelin-1 (ET-1) or tumor necrosis factor-a 
(TNF-a). N-acetyl-cysteine (NAC), a precursor of glutathione (GSH), an intracellular f ee radical scavenger, abolishes the UVB-stimu- 
lated POMC peptide production and secretion. Conclusions are as follows: (l) Cultured human cells of cutaneous origin, namely 
keratinocytes and melanocytes, can produce and express POMC; (2) POMC expression is enhanced by exposure to UVB, possibly 
through a cyclic AMP-dependent pathway; and (3) The action of UVB on POMC production may involve a cellular esponse to oxidative 
stress. 
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1. Introduction 
Proopiomelanocortin (POMC) is a 31 kDa pro-hormone 
protein that is processed to various bioactive peptides 
including adrenocorticotropin (ACTH), melanotropins (a-, 
13-, -,/-MSH), lipotropins, and endorphins [1]. POMC is 
expressed not only in the pituitary gland and in the central 
nervous system [2], but also in peripheral tissues [1-4], 
and in a variety of non-pituitary tumors including 
melanomas [5]. POMC expression and processing culmi- 
nates in the synthesis and release of POMC-derived pep- 
tides, a process that is under multi-hormonal control and 
stimulated by increased intracellular cAMP concentrations 
[1,3,4,6]. Two of the POMC-peptides, ACTH and a-MSH 
are well recognized as regulators of melanogenesis [7]. 
Recent demonstrations of POMC expression in murine [8], 
* Corresponding author: Fax: + 1 (518)2625927. 
and human skin in vivo [9,10] suggest hat local production 
of POMC peptides might play a role in both cutaneous 
melanogenesis a  well as in regulation of the skin immune 
system [7]. 
Melanocytes and keratinocytes are included as members 
of the neuroendocrine and immune systems of the skin 
[ 11,12]. Preliminary studies from different laboratories have 
shown that indeed all these cells were found to contain 
et-MSH [13], immuno-reactive ACTH [9,10] or 13-en- 
dorphin [5,9]. Schauer et al. [14] reported that the normal 
human keratinocytes and epidermal cancer cells, A431, 
synthesize and release both ACTH and ct-MSH to the 
culture medium, and that this process was enhanced by 
UVB irradiation. Recently Wintzen et al. [15] reported that 
normal human keratinocytes produce 13-endorphin and 13- 
lipotropic hormone after stimulation by UV, I L - la  or 
phorbol ester, and Kippenberger et al. [16] demonstrated 
that oL-MSH is expressed in cultured human melanocytes 
and keratinocytes. 
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The above results are consistent with our earlier pro- 
posal that the stimulatory effects of UVB on skin pigmen- 
tation may be mediated through the MSH/MSH receptor 
system [17-19]. In this regard we have recently shown that 
UVB stimulates the production of both POMC and MSH 
receptor mRNA by mouse melanoma cells and trans- 
formed keratinocytes in culture [20]. Here we extend these 
studies to the regulation of POMC peptide production by 
normal human melanocytes and keratinocytes as well as 
human transformed epidermal cells by UVB and other 
agents. We tested the effects of dbcAMP, a modifier of 
POMC expression in other cell systems [21-24]; IL- la,  
tumor necrosis factor (TNFa) and endothelins, UV-sensi- 
tive regulators of melanocytic function [25-32]; and N- 
acetyl-cysteine (NAC), a precursor of glutathione (GSH) 
[33]. Results of these studies are discussed in the context 
of potential mechanisms regulating POMC expression in 
mammalian skin. 
tissue culture plates in quadruplicate. UVB treatment was 
performed when the cultures became 70-80% confluent. 
During UVB irradiation, the culture medium was replaced 
with 0.3 ml phosphate-buffered physiologic saline (PBS). 
Dosages of 5-100 mJ/cm 2 UVB light were used (energy 
range of 260-380 nm with a peak at 302 nm; UVM-57 
LAMP, UVP Inc, California). Immediately after pho- 
totreatment, PBS was removed and serum-free keratino- 
cyte basal medium (which does not contain pituitary ex- 
tract or rEGF) was added to the cells and incubated for 24 
hours at 37°C in a 5% CO 2 atmosphere. After 24 h, the 
media were collected from quadruplicate cultures, pooled 
separately for each conditions tested, and processed for 
extraction of POMC peptides. Cells were collected by 
minimal trypsin treatment, counted with a Fuchs-Rosenthal 
cytometer, before processing for extraction of POMC pep- 
tides. Cell viability was determined by trypan blue exclu- 
sion. 
2. Materials and methods 
2.1. Cell culture 
Normal human melanocytes and keratinocytes were es- 
tablished from foreskins in culture and maintained as 
described previously [28,34]. For melanocytes, Ham's F10 
medium supplemented wilh fetal calf serum, 5%; 12-O-te- 
tradecanoyl phorbol-13 acetate (TPA), 85 nm; isobutyl- 
methyl xanthine (IBMX), 0.1 mM; insulin, 1.0 mM; and 
bovine pituitary extract, 40 ~g protein/ml, were used. 
Keratinocytes were cultured in keratinocyte-SFM (serum- 
free keratinocyte medium, Gibco, Life Technologies, NY) 
containing bovine pituitary extract, 25 txg/ml, and recom- 
binant epidermal growth factor, 5 ng/ml. In both cases, 
streptomycin-penicillin (40 IU/ml), and fungizone (1.25 
p,g/ml) were added to the medium. Melanocytes at pas- 
sages 2-6, and keratinocytes at passages 2 were used for 
these studies. Cells were deprived of TPA effect before 
any experimental treatment by culturing them in keratino- 
cyte-SFM medium containing bovine pituitary extract (25 
[zg/ml) and recombinant epidermal growth factor (rEGF, 
5 ng/ml) 7 days prior to the study of POMC expression 
[35,36]. 
The human melanoma cell line, SK-MELI88 (provided 
by Dr. A. Houghton, MD, Memorial Sloan-Kettering Can- 
cer Center), and human squamous cell carcinoma, C4-1, 
(provided by Dr. M. Reiss, Yale University) were cultured 
in Dulbecco's modified Eagles medium (DMEM) with 1% 
non-essential mino acids. 2% fetal bovine serum, and 8% 
Serum Plus (JRH Biosciences, Lenexa, KS, USA). 
2.2. Exposure to UV light 
In the UVB irradiation experiments, cells were seeded 
at a density of 3 X 105 cells per well in a six-well Coster 
2.3. Treatment with cytokines, endothelin-1, N-acetyl cys- 
teine (NAC), dbcAMP, and TPA 
During the treatment the culture medium was replaced 
with keratinocyte-SFM basal media containing no further 
additions (control), recombinant human IL- I ct (100 pg/ml, 
Genzyme, MA, USA), and human endothelin-1 (10 nM, 
Peptide Institute, Osaka), TPA (100 nm), or dbcAMP (1 
mM). Purified natural human tumor necrosis factor-or 
(TNFtx, provided by Hayashibara Biochemical Laborato- 
ries, Okayama, Japan), was also used in this experiment a  
the doses of 10 JRU/ml, i.e., 5 ng/mi [37]. To test the 
effects of protein kinase C (PKC) on POMC expression, 
some cells were treated with TPA (100 nm) for 3-4 h, 
after which the cells were cultured with TPA-free medium 
for an additional 20 h. Tyrphostin (30 ~M), and genestein 
(1 p~M), purchased from Gibco/BRL Co., were used as a 
tyrosine kinase inhibitors. NAC (500 ~M), purchased from 
Sigma Chemical Co, was used as a precursor of GSH 
which acts as an intracellular f ee radical scavenger [33]. 
All the treatments mentioned above were continued for 24 
h before extraction of POMC peptides or RNA. 
2.4. Extraction of  POMC peptides 
For extraction of peptides, conditioned culture media 
were pooled separately for each condition tested, and 
protease inhibitors (aprotinin, 0.01%; PMSF, lmM) were 
added, and the media were centrifuged at 16 000 × g for 
30 rain. The supernatants were collected, and according to 
the manufacturer's protocol (Peninsula) peptide extraction 
was carried out as follows. An equal volume of peptide 
extraction buffer A (provided with the kit, Peninsula, Cat. 
No. RIK-BA-1), containing 0.1% triflouroacetic acid 
(TFA), was added and centrifuged at 3000 X g for 10 min 
at 4°C. The supernatants were then passed through a pre 
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equilibrated SEP-column containing 200 mg of C 18 (Cat. 
No. RIK-SEPCOL 1, Peninsula). After slowly washing the 
column with buffer A, the peptides were eluted with 3 ml 
of buffer B (60% acetonitrile in 0.1% TFA, Cat. No. 
RIK-BB-1). The eluants were concentrated to dryness in a 
centrifugal concentrator. The residues were dissolved in 
500 Ixl of RIA buffer (NaH2PO 4, 19 mM; Na2HPO 4, 81 
raM; pH 7.4; NaCI, 0.05 M; BSA, 0.1%; Triton X-100, 
0.1%; and NaN 3, 0.01%) for the assays of aMSH and 
ACTH by the kit method (Peninsula). 
Cell pellets were dissolved in 1 ml RIA buffer supple- 
mented with 1% TX-100 and PMSF (1 mM), and aprotinin 
(0.01%), and processed as above for peptide isolation 
through the SEP column. 
For human melanoma cells (SK-MEL188) and trans- 
formed squamous cell carcinoma (C4-1), peptides from 
culture media and cell pellets were extracted as described 
previously [20]. 
2.5. Radioimmunoassay of aMSH and ACTH 
c~-MSH and ACTH in normal human epidermal cells 
were measured using a commercial radioimmunoassay 
(RIA) kit (Peninsula). For human melanoma nd squamous 
cell carcinoma, the RIA were done using a kit from Incstar 
(Stillwater, MN). However both antisera are highly spe- 
cific as the cross reactivities among the POMC peptides, 
such as desacetyl-c~-MSH, diacetyl-a-MSH and deamido- 
a-MSH, 13-MSH, ~-MSH, ACTH, a,13,'y-endorphin, were 
less than 0.01% for rabbit anti-aMSH according to the 
kit's specifications, and as measured directly with the 
peptide standards in our laboratory. Likewise rabbit anti- 
ACTH (1-24) serum does not cross react with other 
POMC peptides, such as ACTH (1-10), ACTH (1-13), 
and oL-MSH (cross reaction were less than 0.01%), but 
shows 100% reactivity with human ACTH (1-24), ACTH 
(1-39). Assay procedures were followed according to the 
kit's instructions. Briefly, 100 ixl of the dissolved material 
was incubated for 24 h with the antibody against a-MSH 
and ACTH followed by re-incubation with J2sI-e~-MSH or 
-ACTH for next 24 h. The bound 125I-peptide was precipi- 
tated with goat anti-rabbit IgG (GARGG) and normal 
rabbit serum. The tubes were centrifuged at 3000 × g for 
20 min, 4°C. The supernatants were discarded and pellets 
were counted in a gamma counter. The concentrations of
the c~-MSH and ACTH were estimated according to the 
standard curves prepared for both peptides, in which known 
quantities of purified a-MSH and ACTH were used to 
compete for 125I-e~-MSH and I25I-ACTH binding to the 
antibodies. Values of ot-MSH and ACTH content were 
normalized to cell number. Levels were expressed as 
pg/0.5 x 10 6 cells or pg/ml  medium for intracellular and 
culture medium levels, respectively. The experiment was 
repeated three times in duplicate, and for statistical analy- 
sis the values were calculated as a percent of control. 
2.6. Statistical analysis 
Statistical analyses of the data pooled from three inde- 
pendent experiments were done using the two-tail paired 
t-test with the help of STATVIEW program (Abacus). The 
differences were considered significant if P < 0.05. 
2.7. Re~'erse transcriptase polymerase chain reaction (RT- 
PCR) 
For RT-PCR studies, cells were grown in 75-cm 2 tissue 
culture flasks (Coming) to approx. 80% confluence. At 20 
h post-treatment of cells with TPA or UVB (10 mJ/cm 2 
for melanocytes; 25 mJ /cm 2 for keratinocytes) as de- 
scribed above, all cells were harvested, washed, pelleted 
by centrifugation, and used to isolate total cellular RNA. 
Briefly, total RNA was extracted using the RNAzol B 
isolation kit following the manufacturer's protocol 
(Cinna/BioTecx Laboratories, Houston, TX). The synthe- 
sis of the first strand cDNA was performed using the 
Superscript pre-amplification system according to the man- 
ufacturer's protocol (Gibco-BRL, Gaithersburg, MD). The 
total cellular RNA (2 Ixg) isolated with the RNAzol B 
isolation kit was reverse transcribed using oligo(dT) as a 
primer. For quantitative PCR, a control gene, glyceralde- 
hyde phosphate dehydrogenase (GAPDH), was amplified 
using primers and conditions described by Robbins and 
McKinney [38]. Only samples that were proven to be free 
from DNA contamination by running PCR amplification 
with GAPDH primers without prior RT were used for the 
experiments. The 260 bp fragment derived from the exon 3 
of the human POMC, was amplified using primers de- 
signed and synthesized commercially (National Bio- 
science, Plymouth, MN) with the following sequence: 
5'-GAG GGC AAG CGC TCC TAC TCC-3' (upper primer) 
and 5'-GGG GCC CTC GTC CTT CTT CTC-3' (lower 
primer). The reaction mixtures contained (NH4)2SO 4
buffer, 25 mM (pH 9.0); MgC12, 2 mM; dNTP, 0.4 mM;' 
and upper and lower primers, 4 IxM each. POMC cDNA 
was heated at 94°C for 3 min., and then amplified for 30 
cycles of 45 sec. at 95°C; 1 min at 58°C; 2 min at 72°C 
with a final extension of 7 min at 72°C. As a negative 
control, RNA samples that were not reverse transcribed, 
were run in parallel. Reverse transcribed pituitary total 
RNA was used as a positive control. The PCR products 
were separated electrophoretically on 1.5% agarose gels, 
stained with ethidium bromide and photographed under 
UV. 
To confirm specificity, the products of RT-PCR were 
transferred tonylon membranes (Oncor, Gaithersburg, MD) 
after denaturation i 0.5 M NaOH and UV crosslinked to 
the membranes. The membranes were prehybridized in 
Hybrizol at 42°C for 4 h and the 3-~P-labeled human 
POMC cDNA (gift of Dr. J. Roberts, Mount Sinai Medical 
Center, NY) was added to fresh hybridization buffer and 
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hybridization was allowed to proceed for an additional 15 
hours at 42°C. The membranes were then washed twice for 
5 min with 2 × SSC plus 0.01% SDS at room temperature, 
followed by two 1-h was]~es with 0.1 x SSC plus 0.1% 
SDS at 60°C. After a final rinse, X-ray film (Kodak XAR) 
was exposed to the membranes at -70°C  for 5 -6  h. 
3. Results and discussion 
UVB stimulated both production and secretion of a-  
MSH and ACTH by normal human melanocytes and kera- 
tinocytes in culture (Table 1). Maximum UVB effects were 
found for melanocytes and keratinocytes at 10 mJ /cm 2 
and 25 mJ /cm 2, respectively. This is in agreement with 
our previous observations that keratinocytes require higher 
dose of UVB irradiation than melanocytes to exhibit phe- 
notypic changes [19,43]. Since UVB can induce production 
of various cytokines and growth factors by melanocytes 
and keratinocytes such as ILl-et, ET-I and TNFa [25- 
29,31], which can affect melanocyte proliferation and pig- 
mentation [30,32], we tes~Eed the possibility that UVB-in- 
duced auto- or paracrine interactions may regulate POMC 
expression. Table 1 shows; that while IL-lcx has small but 
significant (P  < 0.01 or 0.05 for melanocytes; P < 0.001 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
260 -~ 
GADPH -I~ ~ l  ~ 
Fig. 1. Detection of POMC n'aRNA by semiquantitative RT-PCR in 
normal human melanocytes and keratinocytes treated with UVB and 
TPA. Upper panel: 260 bp POMC mRNA from exon 3 (arrow) was 
amplified (30 cycles) using primers described inSection 2. Lower panel: 
amplification of the glycerol phosphate dehydrogenase gene (GAPDH, 
arrow). Human pituitary (positive control, ane 1); buffer (lane 2); DNA 
size markers of 1000, 700, 525,400, 300 and 100 bp (lane 3); untreated 
human keratinocytes (lane 4); human keratinocytes exposed to UVB, 25 
mJ/cm 2 (lane 5); human keratinocytes reated with TPA, 100 nM (lane 
6); negative control (lanes 7, 8, and 9; PCR amplification of RNA 
corresponding to samples in lanes 3, 4 and 5, respectively, without prior 
reverse transcription); untreated human melanocytes (lane 10); human 
melanocytes exposed to UVB, 10 mJ /cm 2 (lane 11); human melanocytes 
treated with TPA, 100 nM (lane 12); negative control (lanes 13, 14, and 
15; PCR amplification f RNA corresponding samples in lanes 10, 11, 
and 12, respectively, without prior reverse transcription). 
AB C DE F 
POMC - I~  
Fig. 2. RT-PCR Southern blot analysis of POMC mRNA expression i
human melanoma cells, SK-MELI88, and human squamous cell carci- 
noma, C4-1. Arrow: POMC amplified mRNA hybridized to the human 
POMC exon 3 cDNA. Lane A, human pituitary (positive control); lane B, 
DNA size markers (as blank); lane C, human melanoma cells (SK- 
MEL188); lane D, negative control for SK-MELI88 (RNA amplified 
without prior reverse transcription); lane E, negative control for human 
squamous cell carcinoma, C4-1 (RNA amplified without prior reverse 
transcription); lane F, C4-1. 
or 0.01 for keratinocytes) stimulatory effect on POMC 
production, ET-1 and TNFa did not affect production of 
ACTH and oL-MSH by either normal human melanocytes 
or keratinocytes. In addition, dbcAMP clearly stimulated 
a-MSH and ACTH production and secretion by both 
melanocytes and keratinocytes (Table 1). This finding is in 
agreement with other reports showing that dbcAMP stimu- 
lates POMC expression and secretion of its peptides in 
different cell lines including mouse melanoma cells [20- 
24]. It is also consistent with a signal transduction system 
through corticotropin releasing hormone receptor (CRH-R) 
that via production of cAMP stimulates POMC activity in 
brain and pituitary gland [39]. Recently, we detected ex- 
pression of CRH-R mRNA in mammalian skin [40]. There- 
fore, we suggest that POMC expression in human 
melanocytes and keratinocytes i  also affected by increases 
in intracellular cAMP content. 
The RT-PCR assay (30 cycles) showed that both UVB 
and TPA stimulated the expression of a 260 bp product 
that migrated identically with a POMC transcript run as a 
positive control (Fig. 1, upper panel); the concentration of 
the amplified fragment of the GAPDH transcript, used as 
an internal control, remained unchanged uring the treat- 
ment (Fig. 1, lower panel). We conclude that the amplified 
260 bp product represents exon 3 of the POMC gene for 
the following reasons: (a) the size as predicted from primer 
sequences, (b) absence in control RNA samples amplified 
without previous reverse transcription (Fig. 1), and (c) 
hybridization to the human POMC cDNA (not shown). 
These results are in agreement with those of Schauer et al. 
[14] obtained with malignant human A431 keratinocytes 
demonstrating an increased expression of POMC gene and 
an increased production and secretion of a-MSH and 
ACTH after UVB and TPA treatment. During the revision 
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of this manuscript Wintzen et al [41] reported the similar 
observation of POMC gene products regulation in normal 
human keratinocytes by UV, TPA, and ILl-et. 
We further extended our studies by testing established 
in vitro lines of human melanoma (Sk-MEL188) and hu- 
man squamous cell carcinoma (C4-1). As with normal 
melanocytes and keratinocytes described above, UVB in a 
dose dependent way stimulated production and secretion of 
txMSH and ACTH in both cell types (Table 2). Further- 
more both cell types expressed the POMC gene as shown 
by RT-PCR amplification followed by hybridization with 
exon 3 cDNA of the POMC gene (Fig. 2). Thus, these 
studies together with previous reports [8,14] strongly indi- 
cate that cultured epithelial and pigment cells of human 
epidermis have the capability to express POMC, and that 
UV irradiation stimulates the production and secretion of 
POMC peptides. 
Since UVB, IL-1, dbcAMP, and MSH are known to 
enhance MSH receptor activity in mouse melanoma cells 
[18,42-44] or human melanocytes [45], it is expected that 
agents that stimulate MSH synthesis and its release may in 
turn result in homologous up-regulation of MSH receptor 
activity and ultimately lead to receptor mediated cascade 
of events for melanocyte activity, in particular melanin 
formation. This, in conjunction with our previous observa- 
tions, supports the notion that at least one action of UVB 
may be expressed through the MSH/MSH receptor system 
[18,42,46]. 
What is the mechanism of UVB-induced POMC expres- 
sion? Since it is reported that the mammalian ultraviolet 
response can involve activation of tyrosine kinases [47] we 
tested the effect of tyrosine kinase inhibitors on POMC 
expression. Neither tyrphostin (30 mM), nor genistein (1 
mM) affected UVB induced MSH and ACTH production 
(data not shown). However, UV irradiation in addition to 
DNA damage, causes lipid peroxidation followed by gen- 
eration of free radicals [48] and depletion of the intra- 
cellular pool of reduced glutathione (GSH), resulting in 
oxidative stress [49]. Evidences are there that active oxy- 
gen species (AOS) produced by UVB irradiation may play 
a role in melanogenesis [5;0]. In this context UV-induced 
AOS could regulate pidermal melanin unit by increased 
expression of melanogenic e~-MSH and ACTH neuropep- 
tides. To test this possibilities, we used N-acetylcysteine 
(NAC) which is readily taken up by cells and is rapidly 
converted to GSH that acts as an intracellular f ee radical 
scavenger [33]. As shown in the Table 3, the UVB-induced 
oL-MSH and ACTH production were suppressed to the 
non-irradiated control evel by NAC (500 ixM) treatment. 
This result suggests that NAC may inhibit the production 
of et-MSH and ACTH possibly through attenuation of the 
oxidative stress triggerd by UVB. Interestingly, several 
other inducers of the UV response were also reported to 
cause oxidative stress [51-53], either through production 
of free hydroxyl radicals and H202 or by reacting with 
free SH groups (alkylating agents). In addition, it was 
reported that dipyrimidine dithymidylic acid (pTpT) which 
is generated by UV radiation, can stimulate melanogenesis 
in both cultured mouse melanoma cells, and in guinea pig 
skin [54]. Such a proposed initiating mechanism for media- 
tion of the UV signal could be compatible with the above 
findings on UV and the expression of melanogenic POMC 
peptides. 
In summary, our data provide evidence that cultured 
human melanocytes and keratinocytes produce POMC pep- 
tides and that such production can be stimulated by UVB 
or dbcAMP. The results further suggest that in human skin 
POMC peptide production might be regulated by cAMP 
and/or oxidative stress pathways. 
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